Article
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine.
PloS one - 13 Oct 2010
Whitaker Hayley C, Kote-Jarai Zsofia, Ross-Adams Helen, Warren Anne Y, Burge Johanna, George Anne, Bancroft Elizabeth, Jhavar Sameer, Leongamornlert Daniel, Tymrakiewicz Malgorzata, Saunders Edward, Page Elizabeth, Mitra Anita, Mitchell Gillian, Lindeman Geoffrey J, Evans D Gareth, Blanco Ignacio, Mercer Catherine, Rubinstein Wendy S, Clowes Virginia, Douglas Fiona, Hodgson Shirley, Walker Lisa, Donaldson Alan, Izatt Louise, Dorkins Huw, Male Alison, Tucker Kathy, Stapleton Alan, Lam Jimmy, Kirk Judy, Lilja Hans, Easton Douglas, Cooper Colin, Eeles Rosalind, Neal David E
Abstract excerpt
BACKGROUND: Microseminoprotein-beta (MSMB) regulates apoptosis and using genome-wide association studies the rs10993994 single nucleotide polymorphism in the MSMB promoter has been linked to an increased risk of developing prostate cancer. The promoter location of the risk allele, and its ability to reduce promoter activity, suggested that the rs10993994 risk allele could result in lowered MSMB in benign tissue...
Read the complete abstract on PubMed